252 related articles for article (PubMed ID: 28618224)
1. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.
Ma H; Lu W; Sun Z; Luo L; Geng D; Yang Z; Li E; Zheng J; Wang M; Zhang H; Yang S; Zhang X
Eur J Med Chem; 2015 Jan; 89():721-32. PubMed ID: 25462278
[TBL] [Abstract][Full Text] [Related]
3. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
4. Structural optimization on a virtual screening hit of smoothened receptor.
Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
[TBL] [Abstract][Full Text] [Related]
5. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
6. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
8. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
Chahal KK; Li J; Kufareva I; Parle M; Durden DL; Wechsler-Reya RJ; Chen CC; Abagyan R
PLoS One; 2019; 14(9):e0214901. PubMed ID: 31539380
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
[TBL] [Abstract][Full Text] [Related]
12. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S
Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
[TBL] [Abstract][Full Text] [Related]
15. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
[TBL] [Abstract][Full Text] [Related]
16. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E1 Inhibits
Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
[TBL] [Abstract][Full Text] [Related]
19. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
20. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
[No Abstract] [Full Text] [Related]
[Next] [New Search]
